Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR

Ioanna Smyrlaki[1,*], Martin Ekman[2,*], Antonio Lentini[1], Nuno Rufino de Sousa[3], Natali Papanicolaou[1], Martin Vondracek[2], Johan Aarum[2], Hamzah Safari[2], Shaman Muradrasoli[4], Antonio Gigliotti Rothfuchs[3], Jan Albert[2,3], Björn Högberg[1] and Björn Reinius[1,#]

[1] Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
[2] Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
[3] Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
[4] Public Health Agency of Sweden, Solna, Sweden.
* Equal contribution
# Correspondence to bjorn.reinius@ki.se

ABSTRACT

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The most widely used method of COVID-19 diagnostics is a reverse transcription polymerase chain reaction (RT-PCR) assay, to detect the presence of SARS-CoV-2 RNA in patient samples, typically from nasopharyngeal swabs. RNA extraction is a major bottleneck in current COVID-19 testing, in terms of turn-around, logistics, component availability and cost, which delays or completely precludes COVID-19 diagnostics in many settings. Efforts to simplify the current methods are critical, as increased diagnostic availability and efficiency would benefit patient care and infection control. Here, we describe methods to circumvent RNA extraction in COVID-19 testing by performing RT-PCR directly on heat-inactivated subject samples as well as samples lysed with readily available detergents. Our data, including benchmarking with 597 clinically diagnosed patient samples against a standardised and sensitive diagnostic system, show that direct RT-PCR is a viable option to extraction-based COVID-19 diagnostics. Furthermore, using controlled amounts of active SARS-CoV-2, we evaluated performance of generic buffers as sample medium for the direct RT-PCR assay, identifying several suitable formulations. We also confirmed the effectiveness of heat inactivation of SARS-CoV-2 by plaque assay. Significant savings in terms of time and cost can be achieved by embracing RNA-extraction-free protocols, that feed directly into the established PCR-based testing pipeline. This could aid the expansion of COVID-19 testing.

INTRODUCTION

The emergence of the novel human coronavirus in late 2019 in the Wuhan region in China rapidly evolved into a global pandemic. The high transmission rates and high proportion of asymptomatic infections led to a massive, worldwide need for rapid, affordable and efficient diagnostic tests, that can be performed in clinical and non-clinical settings [1,2].

Currently, the widely used method of SARS-CoV-2 detection in clinical diagnostics is an RT-PCR assay, detecting the presence of viral RNA in patient samples. Although RT-PCR is widely implemented for the detection of pathogens, including viruses [3] in clinical samples, the implementation of the specific assay for the detection of SARS-CoV-2 has only recently been established. The currently used protocol was developed and optimized for the detection of the novel coronavirus at the Charité University Hospital, in collaboration with institutes in Germany, the Netherlands, China, France, United Kingdom and Belgium [4]. A different test protocol was developed by the Center for Disease Control (CDC) in the United States through comparison and validation of various kits for nucleic acid extraction and the use of alternative probe and primer sets for SARS-CoV-2 detection in clinical samples [5-6]. Routinely, the application of quantitative PCR (qPCR) for the relative quantification of a transcript of interest is preceded by *(1)* the isolation and purification of total RNA from the sample, *(2)* elution and possible concentration of the material, and *(3)* the use of purified RNA in a reverse-transcription (RT) reaction resulting in complementary DNA (cDNA) from the template RNA which is then utilized for the qPCR reaction. However, nucleic acid purification and RT of the resulting RNA into cDNA are not only laborious and time-consuming, but the additional steps requiring manual handling can result in experimental errors. In the case of clinical sampling and diagnostics, the use of a single-reaction kit combining the RT and qPCR reactions is therefore customary. Although single-reaction RT-PCR removes the need for a separate RT reaction, RNA isolation from clinical samples constitutes a major bottleneck in the diagnostic process, as it remains both manually laborious and expensive. Specifically, both the Charité University Hospital and the CDC protocols require the use of RNA purification kits, which not only results in a significant cost increase but has already led to a major supply shortage of such kits. It is therefore crucial that a new test is not only affordable, quick and efficient, but also that it keeps the use of industrial kits to the minimum. Recent attempts have been made to circumvent RNA extraction in COVID-19 detection [7-9].

Here, we established routines for SARS-CoV-2 RNA-extraction-free single-reaction RT-PCR testing (**Fig. 1**) on heat-inactivated nasopharyngeal swab samples in transport medium and compared the results with clinically diagnosed

patient samples, demonstrating the viability of extraction-free SARS-CoV-2 diagnostics. In addition, we evaluate various buffer formulations as alternative transport media, and we provide data showing that SARS-CoV-2 RT-PCR can be performed in presence of high concentration of detergent, allowing testing directly on sample lysates. Importantly, our method builds on clinically established protocols and could easily be integrated to expand ongoing testing pipelines. It is also modular and can be incorporated into alternative approaches of detection utilising PCR.

RESULTS

We started by investigating how transport media used for swab collection affect RT-PCR. To do this, we spiked synthetic full-genome SARS-CoV-2 RNA (SKU102024-MN908947.3, Twist Biosciences) into dilution series of three different transport media (Virocult MED-MW951S, Sigma; Transwab MW176S, Sigma, and Eswab 482C, COPAN) used for clinical sampling at the time of the study (Karolinska University Hospital, Stockholm, Sweden). Each mock sample contained 50,000 synthetic SARS-CoV-2 gRNA copies and 95-0.1% medium, corresponding to 47.5-0.05% medium in the RT-PCR reaction. We performed single-reaction RT-PCR using 10µl sample in a 20µl reaction (TaqPath, Thermo, A15299) and the CDC nucleocapsid 1 (N1) primer-probe set (**Table 1**, Methods) and recorded cycle threshold (C_T) values for the dilution series of the media. We observed inhibitory effects in all three media and, importantly, pronounced variation between media (**Fig. 2a**). Virocult and Transwab demonstrated similar profiles of inhibition, resulting in +2-3 C_T at the highest medium concentrations and minimal inhibition at concentrations below 30% medium in the RT-PCR reaction. Eswab completely impeded detection at high concentrations but reached a similarly low level of inhibition as Virocult and Transwab at 25% concentration in the reaction. To test that the batch of synthetic RNA used did not contain lingering DNA template, we additionally performed RT and qPCR reactions in two separate steps (Methods) including RT+/− controls, which demonstrated the lack of DNA amplification signal when the reverse transcriptase was excluded from the reaction (**Supplementary fig. 1a**). Together, these results indicate minimal or no inhibition of Virocult, Transwab and Eswab at ≤25% in the RT-PCR reaction, corresponding to ≤5µl sample in a 20µl SARS-CoV-2 RT-PCR reaction.

To test whether direct RT-PCR could accurately detect the presence of SARS-CoV-2 in clinical samples we started by obtaining five aliquots of nasopharyngeal swab samples stored in transport medium at −20°C. Aliquots of the same samples had previously been clinically diagnosed using conventional RNA extraction (MagNA Pure 96 DNA and Viral NA SV Kit, Roche Diagnostics 06543588001) followed by RT-PCR, calling three patient samples as SARS-CoV-2 positive and two as negative to the virus (Clinical diagnostics performed at the Karolinska University Hospital, Stockholm). We inactivated the nasopharyngeal samples either by adding MagNA Pure 96 External Lysis Buffer (Roche, 06374913001), used in conventional RNA purification, or by heating at 65°C for 30min, and performed direct RT-PCR using 3µl of sample. We observed a lack of amplification in SARS-CoV-2 positive samples inactivated with External Lysis Buffer (**Fig. 2b-c** and **Supplementary fig. 1b**). However, RT-PCR performed directly on heat-inactivated samples correctly detected SARS-CoV-2 in all positive samples and lacked signal in the negative samples and controls (**Fig. 2b-c**). This indicated the viability in further exploring heat-inactivated direct RT-PCR (hid-RT-PCR) as a method to detect SARS-CoV-2 in clinical samples. We also tested two-step RT and qPCR for SARS-CoV-2 detection on the same clinical samples (Methods), correctly detecting the viral presence and absence (**Supplementary fig. 1c**).

Next, we tested primer-probe set performance in hid-RT-PCR using nasopharyngeal swab samples and primers-probe sets targeting the SARS-CoV-2 genes RNA-dependent RNA polymerase (RdRP), envelope (E), and nucleocapsid (N1) (**Table 1**). We obtained additional heat-inactivated (65°C 30min) nasopharyngeal swab samples called as SARS-CoV-2 positive in previous clinical diagnostics (Methods). We observed, in our setting, a modest difference between N1 and RdRP in hid-RT-PCR (mean and median C_T difference to N1: 0.63 and 0.27, *P*=0.032, Wilcoxon signed-rank test) while the E-gene set appeared at considerably higher C_T values than the other primer-probe sets (mean and median C_T difference to N1: 2.9 and 1.7, *P*=0.00098, Wilcoxon signed-rank test) (**Fig. 2d-e**), in line with previous results [10]. We argue that using short amplicon targets is critical for hid-RT-PCR due to the expected RNA fragmentation during heating, while considerations on the amplicon length should be less important for PCR amplification performed on extracted RNA from fresh samples. Due to the superior performance of N1 in hid-RT-PCR, we focused on this primer-probe set in the deepened analyses of hid-RT-PCR.

Our dilution experiments of medium and spike-in synthetic SARS-CoV-2 RNA had shown limited inhibition at ≤25% medium in the reaction (**Fig. 2a**). However, clinical samples contain additional material from the swab and other unknown and potentially inhibitory agents. In addition, due to potentially large variability between clinical samples, it is important to characterize inhibition curves in multiple individual clinical samples rather than an averaged mix of samples. The optimal amount of sample input in hid-RT-PCR should be a balance between possible inhibition from the sample and the amount of RNA going into the reaction. To identify the optimal range of sample input in

clinical samples, we performed dilution series (10 to 0.01μl) of individual COVID-19 positive heat-inactivated nasopharyngeal swab samples, and found an input of 1-4μl sample in a 20μl RT-PCR reaction to be optimal, avoiding the sharp inhibitory effect at higher amounts of sample input observed in some individual samples, yet minimizing C_T (**Fig. 2f-g**).

To begin to explore whether direct RT-PCR on heat-inactivated samples might allow effective COVID-19 diagnostics, we performed heat inactivation (65°C 30min) of frozen (-20°C) aliquots from 85 clinically diagnosed nasopharyngeal samples and performed hid-RT-PCR blindly to their COVID-19 status. We used 4μl input and primers N1, RdRP, as well as RNase P for assessment of sample integrity. Thereafter, we combined the results of hid-RT-PCR with C_T values from the clinical diagnostics performed on extracted RNA (MagNA Pure 96, Roche Diagnostics, 1:1 input-to-eluate volume, test targeting E and RdRP, Methods). We observed strong correlation between C_T values of extracted and heat-inactivated samples (**Fig. 2h**) and overall agreement of SARS-CoV-2 calls (**Fig. 2i**). However, C_T values for hid-RT-PCR (65°C 30min) on frozen samples were higher than for fresh RNA eluates of the same samples (median 6.7 C_T difference) (**Fig. 2h-i**). This was expected given that *(1)* more RNA was loaded for eluates (2.5*x*, standard 10μl input *vs*. 4μl volume equivalent in hid-RT-PCR), *(2)* RNA extraction of eluates was performed on fresh samples while the aliquots used for hid-RT-PCR had been frozen and stored at –20°C before heat inactivation, *(3)* heating may degrade RNA in presence of RNases and/or metal ions (metal-ion-based RNA cleavage). By performing RNA re-extraction from 19 freeze-thawed aliquots and comparing C_T values to eluates of matched fresh aliquots of the same nasopharyngeal specimens we found the effect of freeze-thaw to result in +2-3 C_T (**Fig. 2j**).

In summary, our data from 85 clinically diagnosed nasopharyngeal frozen samples showed that hid-RT-PCR could be a working option to extraction-based SARS-CoV-2 diagnostics, and that efforts to optimize the hid-RT-PCR protocol for maximum performance would be worthwhile.

Optimisation of hid-RT-PCR

To identify an optimal heat-inactivation program preceding hid-RT-PCR, we subjected 50μl fresh (non-frozen) aliquots of the same clinical nasopharyngeal samples in transport medium to different temperatures and incubation times (65°C 30min; 95°C 5min; 95°C 10min; 95°C 15min; and 98°C 5min; n≥ 11). We observed consistent improvement (reduction) of hid-RT-PCR C_T values in aliquots inactivated at 95°C, 5 min compared to 65°C, 30 min (median C_T change: – 1.3, *P*= 1.1x10^{-5}, Wilcoxon signed-rank test, N1 primer-

probe set) (**Fig. 3a**). Interestingly, all the other high-temperature (≥95°C) conditions tested resulted in similar C_T as the 95°C 5min treatment (*P*> 0.05, FDR-corrected Wilcoxon signed-rank tests) (**Fig. 3a**). Thus, we conclude that inactivation before hid-RT-PCR should be performed at 95-98°C. This result is fortunate and important, since incubation at such high temperature should completely inactivate the virus [11]. Moreover, the stability across incubation times (5-15 min) at high temperature demonstrates a remarkable robustness of the procedure.

Next, we tested whether hid-RT-PCR could be improved by addition of the chemical, thermostable, RNase inhibitor polyvinylsulfonic acid (PVSA), and/or the chelating agent ethylenediaminetetraacetic acid (EDTA) during heat inactivation. PVSA halves *in vitro* RNase A activity (50% inhibition, IC$_{50}$) at the concentration 150μg/ml and halves the RNase activity of E. coli lysate (IC$_{50}$) at 430μg/ml [12]. At the same time, PVSA might inhibit RT-PCR. By performing dilution series of PVSA using synthetic SARS-CoV-2 RNA (SKU102024-MN908947.3, Twist Biosciences) as template, we identified a concentration range with prospective RNase inhibition in the sample yet limited inhibition of RT-PCR (**Supplementary fig. 1d**). We then supplemented fresh aliquots of 20 COVID-19-diagnosed clinical nasopharyngeal samples in transport medium with various amounts of PVSA and/or EDTA, and for EDTA-containing conditions we further performed tests supplementing equimolar amounts of MgCl$_2$ in the RT-PCR mix (12 conditions and 20 samples, n= 240) (**Table 2**). To additionally test the RNA stability in different treatments over time in storage (4°C) we determined the SARS-CoV-2 RT-PCR C_T change in the same samples over different number of days (0, 1, 4 and 7) after heat inactivation. We ranked the treatments within each sample and day, and we observed that 95°C 5min + 150μg/ml PVSA produced the highest score (lowest C_T) followed by 95°C 5min without additives across day 0 to 4 (**Fig. 3b-d** and **Table 2**). The benefit of EDTA and higher concentrations of PVSA only became apparent after 4-7 days in storage (4°C) (**Fig. 3d-e** and **Table 2**). Interestingly, albeit C_T values increased with time the results of the time series showed that heat-inactivated samples are surprisingly stable up to one week in storage at 4°C.

Given the good performance of the 95°C 5min condition without additives (less than 1 C_T difference compared 150μg/ml PVSA, **Fig. 3c**) together with its simplicity in sample handling, we selected this condition for further benchmarking. Finally, to experimentally validate the effectiveness of the thermal inactivation procedure, we propagated SARS-CoV-2 *in vitro* (Methods), and subjected active harvested viral particles to heating at 95°C for 5min. We then performed plaque assays on Vero E6 cells, indeed demonstrating the lack of plaque formation from the heat-inactivated specimens (**Fig. 4**).

Validation of hid-RT-PCR against standardised clinical testing

Having optimised the heat-inactivation conditions, we next benchmarked SARS-CoV-2 hid-RT-PCR (95°C 5 min) using the cobas 6800 system (Roche Diagnostics; hereby referred to as cobas) and a large set of paired clinical nasopharyngeal swab samples as reference. To first test the cobas performance compared to conventional RT-PCR on eluated RNA, we determined C_T values of 21 purified clinical nasopharyngeal swab samples and performed a limit-of-detection experiment with the same sample (dilution from 1:100 to 1:100,000) on both systems, and observed a higher rate of detection and sensitivity for cobas (**Supplementary table 1-2**). Given its performance and the fact that the cobas is a standardized and fully automated system (avoiding manual sample handling) we deemed it to be a suitable system for validation of SARS-CoV-2 hid-RT-PCR. We collected aliquots of 597 clinical nasopharyngeal swab samples diagnosed on the cobas analyser the same day using two targets (primer-probe sets towards ORF1 and E; "Target 1" and "Target 2" cobas SARS-CoV-2, P/N: 09175431190, Roche Diagnostics) and performed heat inactivation (95°C 5 min) followed by SARS-CoV-2 hid-RT-PCR (N1 primer-probe set, 4µl sample input). C_T values of hid-RT-PCR and cobas correlated well and had similar C_T value distributions (P=0.11 and 0.88; N1 *vs.* ORF1 and E, respectively; Kolmogorov–Smirnov test) (**Fig. 5a-b**). In addition to the 597 samples cross-compared with hid-RT-PCR, we plotted 9437 historical nasopharyngeal SARS-CoV-2 C_T values collected on the same cobas machine and observed that the C_T value distribution of the 597 samples was representative of the larger set (P=0.23 and 0.35; ORF1 and E, respectively; Kolmogorov–Smirnov test) (**Fig. 5c-d**). Finally, we classified the COVID-19 status of the 597 nasopharyngeal swab samples on the cobas, either requiring positive signal ($C_T \leq 40$) for both targets (ORF1 and E), or, any target (ORF1 and/or E) to call a sample SARS-CoV-2 positive (**Fig. 5e**, leftmost bars). We plotted a heatmap of SARS-CoV-2 detection (C_T) and observed remarkable agreement between cobas and hid-RT-PCR (**Fig. 5e-g**). Using the diagnostic call of both cobas targets as reference, hid-RT-PCR had an accuracy, sensitivity and specificity of 98.8% (95% confidence interval, CI_{95}: 97.5-99.5%), 96.0% and 99.8%, respectively (**Table 3**). Requiring only one cobas target to call samples SARS-CoV-2 positive, the hid-RT-PCR accuracy, sensitivity and specificity were 97.5% (CI_{95}: 95.9-98.6%), 91.4% and 99.8%, respectively. We observed the performance of hid-RT-PCR (95°C 5 min) using the N1 primer-probe set to be similar to the cobas ORF1 target (**Table 3** and **Fig. 5f-h**). Next, we calculated the sensitivity of hid-RT-PCR at different C_T thresholds and C_T bins (as detected by the most sensitive cobas E-gene target; limit of detection ORF1: 0.009 $TCID_{50}$/ml, E: 0.003 $TCID_{50}$/ml; **Supplementary table 2**) and found that hid-RT-PCR

effectively only lost in sensitivity for samples detected at C_T 35-40 by the cobas E target, i.e. close to the limit of detection (**Fig 5i-j**).

Together, these data demonstrate that a simple heat inactivation program followed by direct RT-PCR using the CDC primer-probe pair N1 detects SARS-CoV-2 with remarkable accuracy, sensitivity and specificity given the ease of the method. As a result, RNA-purification-free SARS-CoV-2 detection is viable, enabling cheap, scalable and rapid testing of COVID-19.

Identification of generic transport buffers suitable for extraction-free SARS-CoV-2 RT-PCR

Our validation demonstrated the diagnostic potential of SARS-CoV-2 hid-RT-PCR for clinical nasopharyngeal samples collected in three commercial transport media (Virocult, Transwab and Eswab). While media inhibition was successfully circumvented by dilution in the RT-PCR reaction (**Fig. 2**), this procedure reduced the input amount of sample (4µl input per 20µl reaction). Additional inhibition data for the widely used Universal Transport Medium (Copan, not clinically used at the site and time of the study) is available in **Supplementary fig. 2**. However, optimally for an extraction-free RT-PCR method, the swab material would be collected in a transport buffer that does not inhibit RT-PCR at all, since this would allow the input volume of sample to be maximized, improving the sensitivity of the assay. A simple and generic transport buffer formulation could also be a cheap alternative to commercial transport media and thus be suitable for mass testing. To identify such buffers, we spiked a fixed amount of active SARS-CoV-2 into 17 different generic buffers (50,000 plaque-forming units (PFU) into volumes of 100µl performed in triplicates, Methods) (buffers listed in **Supplementary table 3**). Subsequently, we performed heat inactivation (95°C 5min) followed by RT-PCR (N1 primer-probe set) using 4, 7, 10, or 13.5µl input to the 20µl RT-PCR reaction to characterize inhibition. This identified several well-performing buffer formulations without inhibition at maximum input (13.5µl per 20µl RT-PCR reaction) such as for example PVSA in nuclease-free water (50µg/ml), TE, Tris buffer and even nuclease-free water (**Fig. 6a**) (Note that DEPC-treated buffers are unsuitable, Methods). Interestingly, physiological saline solution (0.9% NaCl) and 100mM PBS showed marked inhibition at higher input levels, with inhibition profiles similar to Eswab (**Fig. 6a**). Saline and 100mM PBS are thus compatible with SARS-CoV-2 hid-RT-PCR at lower input volumes (4µl input 20µl RT-PCR reaction) but are clearly suboptimal choices of transport buffer for extraction-free RT-PCR.

A workable transport buffer must maintain detectable levels of SARS-CoV-2 several days after sample collection.

We therefore also characterized how C_T values changed with time in storage in the different buffers. We spiked active SARS-CoV-2 into the buffers and stored aliquots in fridge (4°C) and room temperature (21°C) in triplicates for each condition. We collected aliquots after 1, 4 and 7 days in storage and subjected the samples to heat inactivation (95°C 5min) and RT-PCR (N1 primer-probe set), using 4μl sample input in the 20μl RT-PCR reaction for each buffer condition. We plotted C_T values for each buffer, time-point and storage temperature and observed the C_T change for the buffers (**Fig. 6b**). Interestingly, the chemical RNase inhibitor PVSA in water (pH6.5) or 10mM Tris buffer (pH7) produced nearly unchanged C_T throughout a week in storage in fridge as well as room temperature (**Fig. 6b**).

In summary, we have identified simple and affordable buffers suitable for SARS-CoV-2 hid-RT-PCR. Importantly, the buffers identified without RT-PCR inhibition allowed more than 3-fold increase of sample input volume (13.5 *vs.* 4μl), which could improve the sensitivity of the SARS-CoV-2 hid-RT-PCR assay.

Direct RT-PCR on lysed SARS-CoV-2 samples

SARS coronavirus envelopes are self-assembled particles in which the lipid bilayer is a weak spot [13], thus the viral envelope can be ruptured by surfactants and at the same time viral RNA can be released from similarly lysed human cells in the sample [14]. A direct route for SARS-CoV-2 screening could be self-testing using nose and throat swabs, or even on saliva, followed by lysis directly before RT-PCR on unpurified samples. RT-PCR assays directly on detergent-inactivated samples would require an RT-PCR assay resilient to high concentrations of detergent. We monitored the effect of Triton X-100 and Tween-20 on SARS-CoV-2 RT-PCR using spike-in of 50,000 copies of synthetic full-genome SARS-CoV-2 RNA (SKU102024-MN908947.3, Twist Biosciences) and the N1 primer-probe set. C_T values were only modestly affected (+1-2 C_T) when incubated with as much as 5% Triton X-100 or 10% Tween-20 in the RT-PCR reaction (**Fig. 7a-b**). We observed lowered levels of fluorescence in the plateau phase in qPCR at increased concentrations of detergent, without markedly affecting the C_T (**Fig. 7c-d**). To test whether actual SARS-CoV-2 RNA could be detected after direct lysis, we obtained six aliquots of saliva and six combined nose and throat swabs in PBS from six deidentified donors (Methods), of which four had been identified as COVID-19 positive and two as negative in extraction-based routine diagnostics (sample aliquots obtained from the Public Health Agency of Sweden). Notably, these samples were not collected by health care professionals using clinical grade flocked plastic swabs, rather the samples were self-collected using simple cotton swabs (deposition in PBS) and a jar without storage buffer for saliva (Methods). Furthermore, at the time of our experiment, these samples had been frozen, thawed and stored at room temperature for several hours combined. We tested these samples blindly, by mixing 5μl sample (saliva or nose + throat swab) with 5μl of 10 or 20% Triton X-100 and performed the SARS-CoV-2 RT-PCR using the N1 primer-probe set directly on these lysates (10μl sample/Triton X-100 mix in 20μl RT-PCR reactions, Methods). Indeed, all four COVID-19 positive donor individuals were correctly called as SARS-CoV-2 positive in at least one Triton X-100 condition or sample (saliva and/or nose + throat swab), while negative controls lacked signal (**Fig. 7e**).

These initial but principal results demonstrate that direct SARS-CoV-2 RT-PCR can also be applied on detergent-inactivated self-sampled material, opening an alternative route for large-scale population screening.

DISCUSSION

Scalable, rapid and affordable COVID-19 diagnostics could help to limit the spread of SARS-CoV-2, consequently saving lives. However, RNA extraction constitutes a barrier to scale-up of testing. We explored procedures to circumvent RNA extraction by performing RT-PCR directly on heat-inactivated subject samples and sample lysates. Our results show that RT-PCR-based testing for SARS-CoV-2 infection can be performed through significantly simpler protocols and without the use of RNA extraction kits, nor other special kits. The results also show that this can be achieved without major sacrifice in accuracy of determining negative and positive cases. The procedure could be especially useful for massively scaling up SARS-CoV-2 testing, as the logistics and cost of RNA purification could be unworkable in mass testing. Importantly, the direct method is also attractive in settings where repeated, cheaper, and quicker testing is desirable, for example in frequent testing of healthcare personnel. The direct method that we present would also be compatible with downstream sequencing-based detection as an alternative to qPCR.

We determined RT-PCR inhibition profiles of different transport media as well as the optimal amount of reaction input of nasopharyngeal swab samples (**Fig. 2**). Further effort should be invested in similar characterization of many more brands and types of transport media in circulation. We propose that characterization of RT and PCR inhibition should become a standard (requirement) for commercial transport media in the future, as to assist direct testing in forthcoming epidemics. In the ongoing COVID-19 pandemic, we question whether it is at all suitable to deposit COVID-19 samples in conventional transport medium. Instead, we suggest that the swab material could be collected in a generic buffer that does not inhibit RT-PCR, especially as

downstream viral culturing in lab is not meaningful for the vast majority of samples.

Heat inactivation cleaves RNA into shorter fragments, and thus primer and probe considerations in hid-RT-PCR should be more important for its sensitivity than for extraction-based RT-PCR of more intact RNA strands. Accordingly, we observed that the primer-probe set with the shortest amplicon (N1, 72bp) performed best in hid-RT-PCR and the longest amplicon (E, 113bp) performed the worst (**Fig. 2d-e**). Although we did not systematically discern whether relative abundance of SARS-CoV-2 gene copies might have contributed to the observed C_T differences we underscore that short amplicon targets (such as N1) should be used in hid-RT-PCR due the expected RNA fragmentation.

After optimizing heat-inactivation conditions (**Fig. 3** and **4**), we validated hid-RT-PCR using the standardized and sensitive cobas 6800 system (Roche Diagnostics) as reference method (**Fig. 5**) and we observed high accuracy, sensitivity and specificity of hid-RT-PCR (**Table 3**). We propose that the sensitivity of hid-RT-PCR could be improved even more if swab samples were to be collected in a buffer that do not inhibit RT-PCR, as the input amount of RNA could then be increased. Using controlled amounts of active SARS-CoV-2, we evaluated the performance of various buffer formulations in hid-RT-PCR, indeed identifying multiple buffers without RT-PCR inhibition (**Fig. 6a**) as well as capacity to preserve the SARS-CoV-2 signal over 7 days in storage in fridge as well as in room temperature (**Fig. 6b**).

Following this, we hypothesized that the direct RT-PCR pipeline for COVID-19 testing might also be implemented by sampling directly into a lysis buffer containing detergents such as Triton X-100. Lysed samples could immediately be subjected to RT-PCR analysis and diluted in the RT-PCR master mix without intermediate steps. Although the data is limited and the procedure should be refined, our results on self-collected saliva and nose/throat samples using cotton swabs (**Fig. 7e**) show that this strategy is workable. If the sensitivity ultimately proves to be adequate for meaningful decisions on self-isolation to limit spread, then this method could be applied to samples taken by the test-subjects themselves, allowing massive screening of the population.

METHODS

Sample collection: Clinical samples (nasopharyngeal swabs) were collected and deposited in transport medium (Virocult MED-MW951S, Sigma; Transwab MW176S, Sigma; or Eswab 482C, COPAN) at the Karolinska University Hospital, Stockholm, Sweden. For routine diagnostics, 200µl of sample in transport medium was inactivated by addition of 200µl MagNA Pure 96 External Lysis Buffer (06374913001, Roche Diagnostics). Extraction was performed from 100µl

aliquots using MagNA Pure 96 DNA and Viral NA SV Kit (06543588001, Roche Diagnostics) or MGI Easy Magnetic Beads Virus DNA/RNA Extraction Kit (1000006989, MGI) and elution volume 100µl. The samples used in direct lysis experiment (**Fig. 7e**) were self-collected volunteer sample from a COVID-19 clinical screen performed in the Stockholm area, organized by the Public Health Agency of Sweden. For swab samples (nose + throat), two cotton tipped wooden swabs were used. Written instructs were provided to introduce one swabs into the throat via the chin as far back in the throat as possible and scrape for 10-20s then rinse the swab in the provided buffer for 10-15s. Instructions were also given to take a second wooden swab and introduce into the nose and scrape for 10-20s in each nostril, followed by a 10-15s rinse in the same buffer tube as the throat swab. The buffer in the swab test was 100mM PBS pH 7.4. Further instructions were to leave a saliva sample at the same time by spitting 3-4 times in a small jar during a 5-10min period. The samples were picked up and transported to a laboratory for testing typically within 1-10hrs after the sampling. Samples were stored at +4°C and RNA was extracted within 24h and tested using RT-PCR. For the current study, samples were deidentified aliquots of these same samples that had been subsequently frozen at -20°C for approximately 7 days, thawed and kept at room temperature for several hours, before performing the direct lysis experiments described herein.

In this work we also used anonymized or pseudo-anonymized surplus material from samples that had been collected for clinical diagnostics of SARS-CoV-2. Informed consent was not obtained from the patients. This is in accordance with the Swedish Act concerning the Ethical Review of Research Involving Humans, which allows development and improvement of diagnostic assays using patient samples which were collected to perform the testing in question.

Heat inactivation: Nasopharyngeal swab samples in approximately 1ml transfer medium were vortexed and 50µl aliquots of each sample were transferred to 96-well PCR plates which were sealed (adhesive aluminum foil, VWR cat. 60941-112) and subjected to thermal inactivation using a thermal cycler with heated lid and using a thermal sealing mat. Alternatively, approximately 200µl aliquots were inactivated in 1.5ml Eppendorf tubes using a heat block. Before RT-PCR testing, the plates were centrifuged to collect debris in the bottom of the wells, and 4 µl sample for RT-PCR were collected from the liquid upper phase using a 10 µl multi pipette and added to plates containing 16µl TaqPath mastermix. Each time the seal of a plate was opened we replaced the seal with a new seal to avoid cross contamination.

One-step RT-PCR: For reverse transcription and quantitative PCR we used the one-step TaqPath RT-qPCR master mix (Thermo, A15299) according to manufacturer's

instructions. Final reactions of 20µl were formed by mixing 5µl TaqPath master mix, primers-probe mix, sample and RNase free water to fill the reaction. Primer and probe concentrations in the RT-PCR reaction were as follows, E and RdRP: 300nM each primer, 200nM probe; N1 and RdRP: 500nM each primer, 125nM probe. Primer and probe sequences are listed in **Table 1**. The thermal cycling steps were: 25°C for 2 min, 50°C for 15min, 95°C for 2min, and 45 cycles of 95°C for 3s and 56°C for 30s. RT-qPCR was performed on a Step-One-Plus real time PCR machine (Applied Biosystems) using the StepOne Software v2.3. The samples from the self-test screen were subjected to the same protocol as described above but without heat inactivation. Briefly, samples (swab samples in PBS or pure saliva) were mixed with equal volume of 10% or 20% Triton X-100 at room temperature (approximately 5min) before performing RT-PCR using 10µl sample/Triton X-100 mix as input to 20µl RT-PCR reactions. Clinical COVID-19 diagnostics at the Karolinska University Hospital, Stockholm, Sweden were similarly performed using TaqPath and primer-probe sets for E and RdRP and 10µl RNA eluate as sample.

Two-step RT-PCR: Reverse transcription was performed by mixing subject sample (4µl in case of clinical nasopharyngeal swab sample), 1µl 10mM dNTPs, 0.15µl 50µM random hexamers (N8080127, Thermo), 0.1µl RNase inhibitor (2313B, TaKaRa), 0.4µl 0.5% Triton X-100 and RNase free water up to 4.5µl, followed by incubation at 72°C for 3min. The sample was placed on ice and a mix containing 0.5µl 100mM DTT, 2µl 5M betaine, 0.1µl 1M MgCl$_2$, 0.25µl RNase inhibitor (2313B, TaKaRa), 2µl 5x Superscript II buffer, 0.5µl Superscript II (Invitrogen) and water up to 5.5µl was added. The samples were then incubated at 25°C for 10min followed by 42°C for 25min and finally for 70°C for 15min. Amplification of 10µl cDNA (RT mix) using primers and probes described in **Table 1** was performed using BioTaq DNA polymerase (Bio-21040, Bioline) in a 20µl reaction containing 2µl 10x NH4 Reaction Buffer (Bioline), 1.2µl 50mM MgCl$_2$, 0.2µl 100mM dNTP Mix and water up to 20 µl. The thermal cycling steps were: 25°C for 2min, 50°C for 15min, 95°C for 2min, and 45 cycles of 95°C for 3s and 56°C for 30s. qPCR was performed on a Step-One-Plus real time PCR machine (Applied Biosystems) using the StepOne Software v2.3.

Synthetic full-genome SARS-CoV-2 RNA: In control experiments with synthetic RNA (SKU102024-MN908947.3, Twist Biosciences), we used 50,000 copies per reaction. This arbitrary copy number was selected as to limit technical variation in the RT-PCR, and the copy number was calculated from the stock concentration provided by the manufacturer.

Cobas 6800: The cobas 6800 is a fully automated instrument that once samples have been loaded performs extraction, amplification and detection. For details

regarding the assay see Roche Diagnostics document 09179909001-01EN (Doc Rev. 1.0). Roche supplied reagents specific for the cobas SARS-CoV2 analysis are cobas® SARS-CoV-2 (P/N: 09175431190) cobas® SARS-CoV-2 Control Kit (P/N: 09175440190) cobas® 6800/8800 Buffer Negative Control Kit (P/N: 07002238190). Prior to analysis MagNA Pure 96 External Lysis Buffer (06374913001, Roche Diagnostics) were added to all samples at a ratio of 1:1 resulting in 150 ul of each patient samples being analysed. The instrument software version used was 01.03.08.1011.

Gel electrophoresis: Products of RT-PCR were separated by electrophoresis on a 3% agarose gel in 1xTBE buffer. The lengths of the products were determined relative to an Ultra-low Range DNA ladder (Thermo, SM1213). Images were taken using an Imagequant Las4000 camera system (Cytiva).

SARS-CoV-2 in vitro assays: SARS-CoV-2 (GenBank: MT093571.1), originally from the Public Health Agency of Sweden, was propagated on 90% confluent Vero E6 cells (ATCC-CRL-1586) for 3 days at 37°C. Viral supernatant was separated via centrifugation at 300g for 10min and viral titers quantified by Plaque-forming units (PFU). In brief, serial dilutions of viral supernatant were inoculated on 6-well plates seeded with 1 million Vero E6 cells per well (9.6cm^2) for 1 hour at 37°C followed by removal of the inoculum media and two washes with PBS. Overlay medium consisting of 2:3 mix of 3% CMC and DMEM was added, and the plates were incubated at 37°C for 3 days. Plates were then inactivated overnight at room temperature using 1ml of 10% formaldehyde solution, washed and stained with crystal violet for 30min, and plaques were counted manually. For confirmation of viral heat inactivation, 0.5ml of the viral stock was pipetted into 2ml safe-lock microcentrifuge tubes, which were incubated at 95°C for 5min, after which PFU were quantified as above. All work with active *in vitro* expanded SARS-CoV-2 was performed in the Biomedicum BSL-3 Core Facility at Karolinska Institutet.

Test of buffers for SARS-CoV-2 RT-PCR: We obtained or prepared the buffers listed in **Supplementary table 3** and dispensed triplicates of 95µl of each buffer into seven 96-well PCR plates. 5µl viral stock, containing 50,000 PFU of *in vitro* expanded active SARS-CoV-2, was added to each well forming total volumes of 100µl. Plates were subjected to heat inactivation (95°C 5min) in a thermocycler (LifeTouch 48-TC-96, BIOER) followed by hid-RT-PCR (using N1 primer-probe pairs) either directly after sampling (day 0) or after 1, 4, or 7 days in storage in fridge (4°C) or room temperature (21°C). At day 0 we performed RT-PCR using 4, 7, 10, or 13.5µl sample input to a 20µl one-step TaqPath reaction (data shown in **Fig. 6a**), and at day 1, 4, and 7 we performed RT-PCR using 4µl sample input (data shown in **Fig. 6b**). Please note that DEPC-treated water and buffers were not used and are unsuitable because DEPC may inhibit PCR.

Data analysis: Graphical representations of data and statistical testing were performed using R. Effect of optimization parameters over time was modelled using linear regression using CT relative to day 0 as the response variable and time (days), EDTA, PVSA and Mg^{2+} additions as predictors both alone and as interaction terms with time. Accuracy, sensitivity and specificity was calculated using the confusionMatrix function in the caret R package [15].

Data availability
Source and raw data are available at
https://github.com/reiniuslab/COVID19.

Ethics statement
The intent of the work was clinical methods development as a response to the COVID-19 emergency. In this work we used anonymized or pseudo-anonymized surplus material from samples that had been collected for clinical diagnostics of SARS-CoV-2. This is in accordance with the Swedish Act concerning the Ethical Review of Research Involving Humans, which allows development and improvement of diagnostic assays using patient samples which were collected to perform the testing in question. Ethical approval was obtained by the appropriate Swedish Authority (Dnr 2020-01945, Etikprövningsnämnden).

Acknowledgements
This research was supported and funded by the SciLifeLab/KAW national COVID-19 research program project grant (2020.0182), the Swedish Research Council (2017-01723) and the Ragnar Söderberg Foundation to BR. We are grateful to Sten Linnarsson for providing synthetic full-genome SARS-CoV-2 RNA, to Gerald McInerney for providing stocks of SARS-CoV-2, and to members of the Reinius lab for comments and discussions. *In vitro* work with active SARS-CoV-2 was performed at the Biomedicum BSL-3 Core Facility, Karolinska Institutet.

Author Contributions
IS, ME, NRS, NP, JoAa, HS and BR performed experiments. AL and BR analyzed data and prepared figures. ME, MV, SM, AGR, JaAl, BH and BR participated in sample handling and organization. BR supervised the study and wrote the manuscript. All authors participated in manuscript editing and approved the manuscript.

Competing Interests
The authors declare no competing interests.

REFERENCES

1. Taipale J, Romer P, Linnarsson S. Population-scale testing can suppress the spread of COVID-19. medRxiv. May 2020:2020.04.27.20078329. (2020) doi:10.1101/2020.04.27.20078329

2. Ferguson N. M *et al.* Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. (2020) https://spiral.imperial.ac.uk:8443/bitstream/10044/1/77482/8/2020-03-16-COVID19-Report-9.pdf

3. Corman, V. M. *et al*. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. *Eurosurveillance* **17**, 20334 (2012)

4. Corman, V. M. *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* **25**, (2020).

5. Centers for Disease Control and Prevention. Real-Time RT-PCR Panel for Detection 2019-Novel Coronavirus. (2020) https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-for-detection-instructions.pdf

6. Centers for Disease Control and Prevention. Information for Laboratories: 2019-nCoV | CDC. Acceptable Commercial Primers and Probes (2020). https://www.cdc.gov/coronavirus/2019-ncov/lab/index.html.

7. Merindol N. *et al.* Optimization of SARS-CoV-2 detection by RT-QPCR without RNA extraction. (2020) https://www.biorxiv.org/content/10.1101/2020.04.06.028902v1.full.pdf

8. Bruce, E. A. *et al.* RT-qPCR DETECTION OF SARS-CoV-2 RNA FROM PATIENT NASOPHARYNGEAL SWAB USING QIAGEN RNEASY KITS OR DIRECTLY VIA OMISSION OF AN RNA EXTRACTION STEP. *bioRxiv* 2020.03.20.001008 (2020) doi:10.1101/2020.03.20.001008

9. Fomsgaard, A. S. and Rosenstierne, M. W. An alternative workflow for molecular detection of SARS-CoV-2 – escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020. *Eurosurveillance* **25**, 2000398 (2020)

10. Barra, G. B. *et al.* Analytical sensibility and specificity of two RT-qPCR protocols for SARS-CoV-2 detection performed in an automated workflow. *medRxiv* 2020.03.07.20032326 (2020)

11. Chin A. W. H. *et al.* Stability of SARS-CoV-2 in different environmental conditions. The Lancet Microbe. 2020;0(0). doi:10.1016/S2666-5247(20)30003-3

12. Earl C. C. *et al.* Polyvinylsulfonic acid: A Low-cost RNase inhibitor for enhanced RNA preservation and cell-free protein translation. Bioengineered. 2018;9(1):90-97. doi:10.1080/21655979.2017.1313648

13. Khattari, Z. *et al.* SARS Coronavirus E Protein in Phospholipid Bilayers: An X-Ray Study. *Biophys. J.* **90**, 2038–2050 (2006).

14. Rabenau, H. F., Kampf, G., Cinatl, J. & Doerr, H. W. Efficacy of various disinfectants against SARS coronavirus. *J. Hosp. Infect.* **61**, 107–111 (2005)

15. Kuhn M. Building Predictive Models in R Using the caret Package. J Stat Softw. 2008;28(5):1-26. doi:10.18637/jss.v028.i05

Figure 1

Figure 1. Schematic overview of SARS-CoV-2 RT-PCR testing procedure. The currently widely used procedure for COVID-19 testing involves: (**a**) Collection of patient material and deposition of potential SARS-CoV-2 viral particles in transport medium. (**b**) Inactivation of the virus by detergent/chaotropic reagents or by heating. (**c**) RNA extraction. (**d-e**) Transfer to PCR-plate (96/384-well) format in which cDNA synthesis by RT and detection by qPCR may take place. Alternatively, detection can be made by sample barcoding and high-throughput DNA sequencing. (**f-g**) Unlike the widely used approach, which includes an RNA extraction step (c) using industrial RNA extraction kits, direct sample testing circumvents this process, by omitting extraction. Instead, after clinical samples are deposited in transport medium, viral particles are inactivated either through heating or by direct lysis in detergent-containing buffer. The inactivated samples are then used for the downstream RT-PCR diagnostic reaction.

Figure 2

Figure 2. SARS-CoV-2 hid-RT-PCR on frozen nasopharyngeal swab samples. (a) C_T values from RT-qPCR performed on dilution series of transport medium (Virocult, Transwab and Eswab) using 50,000 spiked copies of synthetic full-genome SARS-CoV-2 RNA and the N1 primer-probe set. Lines represent the mean of duplicates, shown individually as dots. ND: not detected. **(b)** Bar plots of C_T from SARS-CoV-2 hid-RT-PCR on clinical nasopharyngeal swabs inactivated with MagNA Pure 96 External Lysis Buffer (ELB) or heat (65°C 30 min). Dots indicate C_T of hid-RT-PCR duplicates and crosses indicate C_T values from diagnostics performed on fresh extracted RNA. Positive controls were extracted RNA from a positive sample (P) and a CDC positive control DNA plasmid (CDC+). Negative controls were extracted RNA from a negative sample (N) and water (H_2O). ND: not detected. **(c)** Amplification plots showing normalized reporter value (ΔRn, linear scale) as a function of qPCR cycle for the experiment and samples described in (b). **(d)** Bar plots of C_T values of 11 positive nasopharyngeal swab samples using primer-probe sets targeting SARS-CoV-2 gene E, N, and RdRP. **(e)** Boxplots of C_T difference in same samples as in (d) comparing E and RdRP with the N1 primer-probe-set. **(f-g)** Line charts of C_T from individual clinical samples (coloured lines) using variable amount of sample input. Shown as absolute C_T (f) or C_T relative to the 10µl input (g). **(h)** Scatter plots of C_T values from clinical diagnostics performed on extracted RNA (y-axis) and hid-RT-PCR (x-axis) of 85 nasopharyngeal swab samples, shown for different primer-probe set comparisons. Rho indicates Spearman correlation of positive samples. ND: not detected. **(i)** Heatmap of C_T values from diagnostics performed on 85 clinical samples using extracted RNA (E, RdRP) and hid-RT-PCR (N1, RdRP), ranked by E gene C_T. Control for sample integrity by RT-PCR for RNase P in the same samples shown on the right. Two patients marked with asterisk (*) were negative in extraction-based diagnostics but positive by hid-RT-PCR. The patients were later re-tested by extraction-based clinical diagnostics and confirmed to be SARS-CoV-2 positive. The patient marked with a ring (o) was not re-tested. Three samples marked with hash (#) were called COVID-19 positive by routine diagnostics but not by any primer-set in hid-RT-PCR. **(j)** Scatter plot of C_T values from 19 matched fresh (y-axis) and freeze-thawed (x-axis) extracted samples, using the E gene (cross) and RdRP (star) primer-probe sets. ND: not detected. hid-RT-PCR shown in this figure was performed on previously diagnosed frozen samples.

Figure 3

Figure 3. Optimisation of heat-inactivation conditions for SARS-CoV-2 hid-RT-PCR. (a) C_T values for aliquots of nasopharyngeal swab samples inactivated at different temperature and time conditions, shown on absolute scale (left) and C_T change relative to the 95°C 5 min condition (right). *P*-values calculated as two-tailed Wilcoxon signed rank tests. *FDR corrected for multiple testing. Median values shown in red. **(b)** Heatmaps of ranks based on absolute C_T values for nasopharyngeal swab samples (n = 20) with or without addition of polyvinylsulfonic acid (PVSA) and/or ethylenediaminetetraacetic acid (EDTA) before performing heat inactivation at 95°C for 5 minutes. For EDTA-containing samples, equimolar supplement of MgCl₂ was added to the RT-PCR reaction as indicated. The same samples were evaluated by RT-qPCR repeatedly at different number of days stored at 4°C after the heat activation. All conditions are listed in Table 2. **(c)** Boxplots of C_T values relative to the 95°C condition without additives, ordered by the rank in (b). **(d)** Change in rank over days of storage at 4°C. Colors and order same as in (b-c). Annotations refer to samples stored for 0 days. **(e)** Change in C_T values over days stored at 4°C across different conditions. Thick line and ribbon indicate fitted LOESS curve and ±95% confidence interval, respectively. The dashed line indicates the 95°C (without additive) condition.

Figure 4

Figure 4. Heat-inactivation of SARS-CoV-2 confirmed by plaque assay. Box plots showing the number of plaque forming units (PFU) observed after heat inactivation (95°C 5 min, left) of *in vitro* propagated active SARS-CoV-2 as well as for a dilution series of SARS-CoV-2 without heat inactivation (right), with circles indicating the values of individual replicates. Virus was added to 9.6cm^2 dishes seeded with 1 million Vero E6 cells and plaque assays performed as described in Methods. Undiluted samples contained 2.5 million PFU of SARS-CoV-2. Representative images are shown below each condition (scale bar 5mm).

Figure 5

Figure 5. Validation of SARS-CoV-2 hid-RT-PCR. (a) Scatter plots of C_T values from clinical diagnostics performed on the Roche Diagnostics cobas 6800 (y-axis) and hid-RTq-PCR (x-axis) for 597 nasopharyngeal swab samples, shown for different primer-probe set comparisons. Rho indicates Spearman correlation of positive samples. ND: not detected. **(b)** Histograms of C_T values from 597 paired nasopharyngeal swab samples shown for the following primer-probe sets and conditions: cobas ORF1, cobas E, and hid-RT-PCR N1. ND: not detected. **(c)** Histograms of C_T values from 9437 clinical samples analysed on a cobas 6800, show for ORF1 (left) and E (right). **(d)** Scatter plots of C_T values from 9437 clinical samples analysed on a cobas 6800. Rho indicates Spearman correlation of positive samples. ND: not detected. **(e)** Heatmap of C_T values from diagnostics performed on 597 clinical nasopharyngeal swab samples using the cobas 6800 (ORF1 and E primer-probe sets) and hid-RT-PCR (N1). The bars to the left indicate the clinical call from the cobas diagnostics, considering detection either in both or only one (any) primer-probe set for the diagnostic call. **(f-h)** Confusion matrix of diagnostic call from cobas 6000 and hid-RT-PCR (N1) for the data shown in (e). **(i)** Percent sensitivity of hid-RT-PCR (N1) using cobas ORF1 and E primer-probe sets as reference, shown as a function of C_T threshold for the same sample as detected by the cobas primer-probe set E. The red lines denote the cumulative sensitivity below the given C_T threshold and the bars denote the sensitivity in 5-C_T bins. **(j)** Same as (i) but using cobas ORF1 and/or E primer-probe sets as reference for calculating sensitivity.

Figure 6

Figure 6. Identification of generic transport buffers optimal for SARS-CoV-2 hid-RT-PCR. (**a**) Line charts of C_T values (y-axis) from hid-RT-PCR (N1 primer-probe pair) for different volume of input sample (13.5, 10, 7, or 4µl to a 20µl reaction; x-axis), showing the inhibition profile of different transport buffers and media. The experiment was performed by adding equal amount of *in vitro* expanded SARS-CoV-2 to each buffer condition in experimental triplicates (dots). The dotted black lines indicate PVSA in H_2O condition, included for comparison. The buffers are ordered according to minimal C_T. (**b**) Line charts of C_T values (y-axis) from hid-RT-PCR (N1 primer-probe pair, 4µl input to 20µl reactions) of *in vitro* expanded SARS-CoV-2 stored in different buffers for up to 7 days (x-axis) in fridge (4°C, square) or room temperature (21°C, triangle) before subjecting the samples to heat inactivation (95°C 30 min) and hid-RT-PCR. The data is shown as individual replicates (points, n=3) and median (line).

Figure 7

Figure 7. **Direct SARS-CoV-2 RT-PCR detection from lysate.** (**a-b**) Line charts of C_T values (y-axis) from RT-qPCR performed with different percent (vol./vol.) Triton X-100 (a) or Tween-20 (b) (x-axis) in the reaction. (**c-d**) Amplification plots showing normalized reporter value (ΔRn, linear scale) as a function of qPCR cycle for the experiments and samples described in (a-b). (**e**) Barplots of C_T from SARS-CoV-2 RT-PCR using the N1 primer-probe set performed directly on lysed donor samples after storage and freeze thaw from self-sampling (saliva or nasal + throat swab suspensions taken with cotton tipped wooden sticks) without purification. Percent Triton X-100 indicates the percentage detergent in the sample (half concentration in the RT-PCR reaction). Crosses indicate C_T values from diagnostics performed on extracted RNA from fresh aliquots.

Table 1

Table 1. Primers and probes used for SARS-CoV-2 RT-PCR.

Name	Amplicon length (bp)	Description	Sequence (5' to 3')
N1	72	Forward	GACCCCAAAATCAGCGAA AT
		Reverse	TCTGGTTACTGCCAGTTGAATCTG
		Probe	**FAM-** ACCCCGCATTACGTTTGGTGGACC **-BHQ1**
E	113	Forward	GGAAGAGACAGGTACGTTAATA
		Reverse	AGCAGTACGCACACAATCGAA
		Probe	**FAM-** ACACTAGCCATCCTTACTGCGCTTCG **-BHQ1**
RdRP	81	Forward	GTCATGTGTGGCGGTTCACT
		Reverse	CAACACTATTAGCATAAGCAGTTGT
		Probe	**FAM-** CAGGTGGAACCTCATCAGGAGATGC **-BHQ1**
RNase P	65	Forward	AGATTTGGACCTGCGAGCG
		Reverse	GAGCGGCTGTCTCCACAAGT
		Probe	**FAM-** TTCTGACCTGAAGGCTCTGCGCG **-BHQ1**

Table 2

Table 2. Heat-inactivation conditions tested for SARS-CoV-2 hid-RT-PCR optimisation. Related to Fig. 3b-e, with corresponding colour code to the left in the table.

Condition	Concentration in heat inactivation		Concentration in RT-PCR		Mg²⁺ supplement in RT-PCR
	EDTA (mM)	PVSA (μg/ml)	EDTA (mM)	PVSA (μg/ml)	
95°C 5 min	0	0	0	0	-
95°C 5 min, 1mM EDTA	1	0	0.15	0	-
95°C 5 min, 10mM EDTA	10	0	1.50	0	-
95°C 5 min, 1mM EDTA, Mg2+	1	0	0.15	0	+
95°C 5 min, 10mM EDTA, Mg2+	10	0	1.50	0	+
95°C 5 min, 150μg/ml PVSA	0	150	0	22.5	-
95°C 5 min, 300μg/ml PVSA	0	300	0	45	-
95°C 5 min, 400μg/ml PVSA	0	400	0	60	-
95°C 5 min, 1mM EDTA, 300μg/ml PVSA	1	300	0.15	45	-
95°C 5 min, 10mM EDTA, 300μg/ml PVSA	10	300	1.50	45	-
95°C 5 min, 1mM EDTA, 300μg/ml PVSA, Mg2+	1	300	0.15	45	+
95°C 5 min, 10mM EDTA, 300μg/ml PVSA, Mg2+	10	300	1.50	45	+

Table 3

Table 3. Accuracy, sensitivity and specificity of SARS-CoV-2 hid-RT-PCR (95°C 5 min) using the Roche cobas 6800 analyzer as diagnostic reference. Each parameter was calculated using the cobas diagnostic call as reference, either requiring both cobas primer-probe sets producing signal ($C_T \leq 40$) to call a sample COVID-19 positive, or, requiring only one (any) cobas primer-probe set producing signal to call a sample positive. As comparison, the parameters were calculated also for the cobas ORF1 primer-probe set, using the more sensitive cobas E primer-probe set as the reference (parameters calculated using the same samples as for hid-RT-PCR). Primer-probe sets used in the comparisons within brackets. Binominal test *P*-values. N= 597 fresh nasopharyngeal swab samples.

Comparison	Accuracy			Sensitivity	Specificity
	Estimate	CI$_{95\%}$	*P*-value		
hid-RT-PCR (N1) *vs.* cobas, both primers (E and ORF1):	98.8	97.5–99.5	4.8E-63	96.0	99.8
hid-RT-PCR (N1) *vs.* cobas, any primer (E and/or ORF1):	97.5	95.9–98.6	2.6E-60	91.4	99.8
cobas ORF1 *vs.* cobas E:	97.7	96.1–98.7	1.8E-61	91.4	100.0

Supplementary figure 1

Supplementary figure 1. (**a**) Amplification plots showing normalized reporter value (ΔRn, linear scale) as a function of qPCR cycle for two-step RT and qPCR performed on synthetic full-genome SARS-CoV-2 RNA (SKU102024-MN908947.3, Twist Biosciences) including (RT+) or excluding (RT-) the reverse transcriptase. (**b**) Agarose gel electrophoresis of RT-PCR products for reactions described in Fig.2e, but in this case using primers and probes for gene E. (**c**) Amplification plots showing normalized reporter value (ΔRn, linear scale) as a function of qPCR cycle for the samples described in Fig. 2e-f, but using two-step RT and qPCR instead of the single-step TaqPath RT-qPCR (Methods). (**d**) Relative cycle threshold (C_T) values of SARS-CoV-2 RT-PCR using the N1 primer-probe set and a dilution series of the chemical RNase inhibitor polyvinylsulfonic acid (PVSA). To test the inhibition of PVSA in RT and PCR reactions separately, we used either synthetic full-genome SARS-CoV-2 RNA (blue dots and line line) or plasmid DNA (CDC positive control) (blue dots and line) as template in the RT-PCR reaction. C_T values are shown relative to reactions without PVSA (conc.= 0). The lines indicate the median of triplicate measurements.

Supplementary figure 2

Supplementary figure 2. C_T values from RT-PCR performed on dilution series of Universal Transport Medium (UTM, Copan) using 50,000 spiked copies of synthetic full-genome SARS-CoV-2 RNA and the N1 primer-probe set. Lines represent the mean and the values of individually replicates (n=4) are shown as dots. Mean values for Virocult, Transwab and Eswab are shown as dashed lines, included for comparison.

Supplementary table 1

Supplementary table 1. C_T values for 21 clinical nasopharyngeal swab samples quantified using cobas 6800 and TaqPath SARS-CoV-2 RT-PCR on eluted RNA. We observed dropout of detection in four positive samples in RT-PCR on eluted RNA. ND: Not detected (C_T >40) ViCu: Virocult. TSw: Transwab.

Sample medium	cobas 6800		RT-PCR (eluate)	
	ORF1	E	RdRP	E
ViCu	32.83	33.89	32.50	34.28
ViCu	22.95	23.10	18.57	18.12
ViCu	32.08	33.15	32.47	33.84
ViCu	30.23	30.95	29.36	29.94
TSw	30.67	31.54	30.63	30.47
ViCu	34.89	37.65	35.77	ND
ViCu	20.22	20.29	17.45	17.35
TSw	24.35	24.50	24.14	23.46
TSw	25.98	26.27	26.05	25.17
TSw	33.92	35.88	ND	33.94
TSw	23.95	24.09	23.33	22.59
TSw	27.33	27.61	26.62	26.32
NA	32.24	33.25	34.28	32.69
NA	33.02	33.95	ND	ND
NA	33.08	34.31	33.54	33.55
ViCu	ND	ND	ND	ND
ViCu	ND	ND	ND	ND
ViCu	ND	ND	ND	ND
ViCu	ND	ND	ND	ND
ViCu	ND	ND	ND	ND
ViCu	ND	ND	ND	ND

Supplementary table 2

Sample dilution	Replicate	cobas 6800	RT-PCR (eluate)	cobas 6800	RT-PCR (eluate)
		E	E	ORF1	RdRP
1:100	1	35.16	34.98	35.14	33.18
	2	34.97	ND	34.95	33.89
	3	35.26	32.86	34.60	32.92
1:1000	1	37.35	36.53	36.32	33.90
	2	36.25	35.36	36.06	34.55
	3	36.68	ND	35.88	35.36
1:10,000	1	37.91	35.31	37.05	35.55
	2	38.71	ND	ND	ND
	3	39.09	ND	ND	ND
1:100,000	1	ND	ND	ND	ND
	2	ND	ND	ND	ND
	3	ND	ND	ND	ND

Supplementary table 3

Supplementary table 3. Generic buffers evaluated for SARS-CoV-2 hid-RT-PCR.

Buffer	Composition	Measured pH	Company catalog number (if available)
PVSA in H_2O pH6.5	Polyvinylsulfonic acid in H_2O (50µg/ml)	6.5	Sigma 278424, Ambion AM9932
TE + 4% sucrose pH7.0	TE (10 mM Tris; 0.1mM EDTA) + 4% sucrose	7.0	Invitrogen AM9858
Tris buffer 10mM pH7.0	10mM Tris buffer	7.0	
PVSA in Tris buffer pH7.0	PVSA in 10mM Tris buffer (50µg/ml PVSA)	7.0	
Tris-HCl 5mM pH7.4	Tris-HCl 5mM	7.4	
TE pH7.0	TE (10 mM Tris + 0.1mM EDTA)	7.0	Invitrogen AM9858
PBS 10mM pH7.5	10mM PBS	7.5	Invitrogen AM9624
Sodium citrate 1mM pH7.6	1mM Sodium citrate	7.6	
H_2O	H_2O	6.4	Ambion AM9932
PVSA in 1mM Sodium citrate pH7.5	PVSA in 1mM Sodium citrate (50µg/ml PVSA)	7.5	
TE + 4% sucrose pH8.0	TE (10 mM Tris; 0.1mM EDTA) + 4% sucrose)	8.0	Invitrogen AM9858
TE pH8.1	TE (10 mM Tris 0.1mM EDTA)	8.1	Invitrogen AM9858
HBSS pH8.4	HBSS (Hanks' Balanced Salt solution)	8.4	Gibco 14025-092
PBS 100mM pH7.7	100mM PBS	7.7	Invitrogen AM9624
Saline 0.9% pH5.8	0.9% NaCl in 1L water	5.8	
DMEM pH7.9	DMEM (Dulbecco's Modified Eagle Medium)	7.9	Sigma D5796
Citrate buffer pH6.2	Citrate buffer (0.04M Sodium citrate dihydrate; 0.06M Citric acid)	6.2	